RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.1,[2] Today’s approval follows the FDA’s decision to grant Breakthrough Therapy Designation (BTD) in March 2020 and to initiate a Priority Review of the Biologics License Application (BLA) in December 2020. This indication is approved under accelerated approval based on overall response rate and duration of response.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.1 “Today’s FDA approval is an important development for people living with non-small cell lung cancer with exon 20 insertion mutations who, until now, have had no approved treatment options to target their disease,” said Jill Feldman, co-founder of the EGFR Resisters, an advoc...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Adenocarcinoma | Alcoholism | Alimta | Allergy & Immunology | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Conferences | Constipation | Corticosteroid Therapy | Cough | Dermatitis | Dermatology | Epidemiology | Food and Drug Administration (FDA) | Genetics | Grants | Health Insurance | Health Management | Heart | HER2 | Hypertension | Infectious Diseases | Insurance | International Medicine & Public Health | Interstitial Lung Disease | Laboratory Medicine | Learning | Legislation | Lung Cancer | Molecular Biology | Neurology | Neuroscience | New York University | Non-Small Cell Lung Cancer | Opthalmology | Oral Cancer | Pain | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Potassium | Pregnancy | Pulmonary Hypertension | Science | Singapore Health | Skin | Skin Biopsy | Skin Cancer | Sodium | Squamous Cell Carcinoma | Statistics | Study | Tarceva | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Websites | WHO | Women